This analysis examines the historical and forecast performance for Organon in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Organon's performance against key rivals in the ethical pharmaceutical sector Evaluate Organon's prospects out to 2012, following the recent $14.8 billion acquisition bid by US-based Big Pharma Schering-Plough Learn how Organon's innovative late-stage pipeline, from which six new products are set to launch, is central to the company's healthy outlook